Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

Peter Hillmen,Andy C. Rawstron,Kristian Brock,Samuel Munoz Vicente,Francesca Yates,Rebecca Bishop,Rebecca Boucher,Donald Macdonald,Christopher Fegan,Alison McCaig,Anna Schuh,Andrew R. Pettitt,John G. Gribben,Piers E.M. Patten,Stephen Devereux,Adrian Bloor,Christopher P. Fox,Francesco Forconi,Talha Munir

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

2019

Peter Hillmen
Andy C. Rawstron
Kristian Brock
Samuel Munoz Vicente
Francesca Yates
Rebecca Bishop
Rebecca Boucher
Donald Macdonald
Christopher Fegan
Alison McCaig
Anna Schuh
Andrew R. Pettitt
John G. Gribben
Piers E.M. Patten
Stephen Devereux
Adrian Bloor
Christopher P. Fox
Francesco Forconi
Talha Munir

PURPOSEThe treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both sig...

Keywords:

Chronic lymphocytic leukemia
Pathology
Ibrutinib
Oncology
Refractory Chronic Lymphocytic Leukemia
Medicine
Internal medicine
Venetoclax
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

102

Citations